· Published by Health Canada · Official notice
| Brand name | Product UPC |
|---|---|
| Product | |
| Product |
Notice about Health Canada advisories
Contact: BGTD
Therapeutic Products Programme
Tunney's Pasture
Address Locator #0603C
Ottawa, Ontario
KlA 0L2
March 24, 1999
Dear Sir/Madame:
The Therapeutic Products Programme (TPP) of Health Canada wishes to provide the following updated information regarding Abbokinase (Urokinase for Injection).
As indicated in our previous correspondence of February 4, 1999, Good Manufacturing Practice deficiencies were identified, last fall during inspections by the US FDA, of Abbott Laboratories and of its supplier of the human neonatal kidney cells used to manufacture Abbokinase. As a result of those deficiencies and as mandated by the US FDA:
As a result of the additional in-process testing, three unfinished lots of in-process material which were not manufactured into finished Abbokinase or distributed, were found to contain reovirus. Abbott is working to determine the extent and the source(s) of the reovirus contamination.
Reovirus is an adventitious agent that should not be present at any step in the production of Abbokinase. Although a number of studies in the literature suggest that the heat inactivation step performed during the further manufacturing of the in-process material into Abbokinase should render reovirus non-infectious, assurance has been provided by Abbott that any in-process material that contains reovirus will not be used to manufacture finished drug product. Moreover, if any lots of Abbokinase are found to contain reovirus, they will not be subject to distribution. Lots of Abbokinase currently on the market have tested negative for reovirus in Abbott's preliminary test; however, this test has not yet been fully validated.
Most reovirus infections are asymptomatic or produce minor upper respiratory or gastrointestinal symptoms. While association of reovirus infection with other human diseases has been reported, a causal link with other diseases has not been established.
Abbott has not yet completed validation of the additional tests requested by the FDA for finished product. Additional finished lots of Abbokinase will not be available for use until further testing has been completed.
Results of the investigations conducted by Abbott following the FDA inspection, indicate that the cell lines used during the past 2 years for the production of Abbokinase were free of HIV, HBV and HCV although the tests have not been fully validated. The revalidation of the inactivation of viruses by heat treatment and the removal of viruses during the purification process is ongoing; all these studies are scheduled to be completed by end of June 1999.
The finding of reovirus contamination of in-process product illustrates continuing concerns regarding the impact of deviations observed during the US FDA inspections and that the deficiencies noted could increase the risk of transmitting infectious agents. TPP would like to reiterate the information and recommendations in its letter of February 4, 1999 to Medical Chiefs of hospitals in Canada:
Yours sincerely,
(Original signed by)
K. Bailey, D.Phil.
Director
Bureau of Biologics and Radiopharmaceuticals
Tel: (613) 957-8064
Fax: (613) 957-6302
E-mail: Keith_Bailey@hc-sc.gc.ca